Table 1.
Baseline characteristics of 72 COPD exacerbation patients requiring emergency department admissions
Baseline characteristics (n=72) | |
---|---|
Age, year | 75.17±7.94 |
Male, n (%) | 72 (100) |
BMI, kg/m2 | 21.98±4.57 |
FEV1/FVC ratio, % | 55.34±9.86 |
FEV1 % predicted normal, % | 40.12±15.70 |
GOLD 1, n (%) | 1 (1.39) |
GOLD 2, n (%) | 13 (18.06) |
GOLD 3, n (%) | 43 (59.72) |
GOLD 4, n (%) | 15 (20.83) |
FVC% predicted normal, % | 50.15±17.10 |
Tobacco use, pack-years | 61.29±30.69 |
Current smoker, n (%) | 33 (45.8) |
Ex-smoker, n (%) | 39 (54.2) |
ICS + LABA, n (%) | 58 (80.56) |
Inhaled anticholinergics, n (%) | 56 (77.78) |
Oral corticosteroid, n (%) | 14 (19.44) |
Short term oral antibiotics, n (%) | 7 (9.7) |
Oral methylxanthines, n (%) | 52 (72.22) |
Anthonisen criteria ≥2, n (%) | 52 (72.22) |
WBC, 109/L | 10.52±4.19 |
CRP, mg/L | 34.97±48.02 |
PCT, ng/mL | 0.2012±0.4315 |
Exacerbation in the sequential 1 year, n (exacerbation/person/year) | 38 (0.52) |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global Initiatives for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting beta-agonists; PCT, procalcitonin; WBC, white blood cell.